Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Conferences
- AACR25
- AACR24
- AACR23
- AACR22
- AACR21
- AACR20
- AACR19
- AACR18
- AACR17
- AACR16
- AACR15
- AACR14
- AACR EORTC Mol Targets
- AACR IO
- AAI ASGCT
- ASCO GI
- ASCO GU
- ASCO-SITC
- ASCO26
- ASCO25
- ASCO24
- ASCO23
- ASCO22
- ASCO21
- ASCO20
- ASCO19
- ASCO18
- ASCO17
- ASCO16
- ASCO15
- ASCO14
- ASH25
- ASH24
- ASH23
- ASH22
- ASH21
- ASH20
- ASH19
- ASH18
- ASH17
- ASH16
- ASH15
- AUA
- BMT
- CIML40
- CIMT
- EACR
- EAU
- ECCO
- EHA iCML
- ESMO25
- ESMO24
- ESMO23
- ESMO22
- ESMO21
- ESMO20
- ESMO19
- ESMO18
- ESMO17
- ESMO16
- ESMO14
- JPM22
- JPM20
- SABCS
- SITC25
- SITC 2024
- SITC 2023
- SITC 2022
- SITC 2021
- SITC 2020
- SITC 2019
- SITC 2018
- SITC 2017
- SITC 2016
- SITC 2015
- SITC 2014
Targets
- ADC
- Adenosine
- AI & ML
- Autoimmune
- Bispecifics / Trispecifics
- Cytokines
- DDR
- Epigenetics
- gamma delta T cells
- MYC
- Neoantigens
- NK Cells
- RAS
- SERDs
- STING
- TIGIT
- TLRs
About
Contact
Pricing
Immuno-Oncology
Protein Degraders
Cell Therapy
Interviews
Premium Content
AACR26
Login

Pointed ironies: SERD wars, ADC hype, and what really works in breast cancer

ASCO Preview on Breast Cancer

Terms of Use & Privacy Policy
Copyright © 2010-26 Biotech Strategy Blog

error: Content is protected !!